WT1 marker is not sufficient for distinguishing between melanoma and melanocytic nevi

Journal of Cutaneous Pathology

Volumn 36, Issue 10, 2009, Pages 1077-1082

  Rosner, Karli ^a,b   Mehregan, Darius R ^b,c   Moussai, Darius ^c   Abrams, Judith ^b   Tromp, Gerard ^b   Mehregan, David A ^b,c  

^a KARMANOS CANCER INSTITUTE   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Pinkus Dermatopathology Laboratory   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; WT1 PROTEIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; JUVENILE MELANOMA; MAJOR CLINICAL STUDY; MALE; MELANOCYTIC NEVUS; MELANOMA; PROTEIN EXPRESSION; RELIABILITY; SENSITIVITY AND SPECIFICITY; TUMOR DIFFERENTIATION;

AGED; ANTIBODIES, MONOCLONAL; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; MIDDLE AGED; NEVUS, PIGMENTED; SENSITIVITY AND SPECIFICITY; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; WT1 PROTEINS;

EID: 69449104982     PISSN: 03036987     EISSN: 16000560     Source Type: Journal    
DOI: 10.1111/j.1600-0560.2009.01224.x     Document Type: Article

References (27)

1. Perry BN, Cohen C, Govindarajan B, Costmis G, Arbister JL. Wilms' tumor 1 expression present in most melanomas but nearly absent in nevi. Arch Dermatol 2006 142 : 1031.
2. Wagner N, Panelos J, Massi D, Wagner KD. The Wilms' tumor suppressor WT1 is associated with melanoma proliferation. Pflugers Arch 2008 455 : 839.
3. Lüdecke HJ, Senger G, Claussen U, Horsthemke B. Construction and characterization of band-specific DNA libraries. Hum Genet 1990 84 : 512.
4. Kirschner KM, Hagen P, Hussels CS, Ballmaier M, Scholz H, Dame C. The Wilms' tumor suppressor Wt1 activates transcription of the erythropoietin receptor in hematopoietic progenitor cells. FASEB J 2008 22 : 1.
5. Hammes A, Guo JK, Lutsch G, et al. Two splice variants of the Wilms' tumor 1 gene have distinct functions during sex determination and nephron formation. Cell 2001 106 : 319.
6. Kreidberg JA, Sariola H, Loring JM, et al. WT-1 is required for early kidney development. Cell 1993 74 : 679.
7. Herzer U, Crocoll A, Barton D, Howells N, Englert C. The Wilms' tumor suppressor gene wt1 is required for development of the spleen. Curr Biol 1999 9 : 837.
8. Lee SB, Haber DA. Wilms' tumor and the WT1 gene. Exp Cell Res 2001 264 : 74.
9. Rosenfeld C, Cheever MA, Gaiger A. WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies. Leukemia 2003 17 : 1301.
10. Miyoshi Y, Ando A, Egawa C, et al. High expression of Wilms' tumor suppressor gene predicts poor prognosis in breast cancer patients. Clin Cancer Res 2002 8 : 1167.
11. Oji Y, Yamamoto H, Nomura M, et al. Overexpression of the Wilms' tumor gene WT1 in colorectal adenocarcinoma. Cancer Sci 2003 94 : 712.
12. Oji Y, Nakamori S, Fujikawa M, et al. Overexpression of the Wilms' tumor gene WT1 in pancreatic ductal adenocarcinoma. Cancer Sci 2004 95 : 583.
13. Timár J, Mészáros L, Orosz Z, Albini A, Rásó E. WT1 expression in angiogenic tumours of the skin. Histopathology 2005 47 : 67.
14. Nakatsuka S, Oji Y, Horiuchi T, et al. Immunohistochemical detection of WT1 protein in a variety of cancer cells. Mod Pathol 2006 19 : 804.
15. Rodeck U, Bossler A, Kari C, et al. Expression of the wt1 Wilms' tumor gene by normal and malignant human melanocytes. Int J Cancer 1994 59 : 78.
16. Patmasiriwat P, Fraizer G, Kantarjian H, Saunders GF. WT1 and GATA1 expression in myelodysplastic syndrome and acute leukemia. Leukemia 1999 13 : 891.
17. Tamaki H, Ogawa H, Ohyashiki K, et al. The Wilms' tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes. Leukemia 1999 13 : 393.
18. Miwa H, Beran M, Saunders GF. Expression of the Wilms' tumor gene (WT1) in human leukemias. Leukemia 1992 6 : 405.
19. Bergmann L, Miething C, Maurer U, et al. High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome. Blood 1997 90 : 1217.
20. Satoh F, Tsutsumi Y, Yokoyama S, Osamura RY. Comparative immunohistochemical analysis of developing kidneys, nephroblastomas and related tumors: considerations on their histogenesis. Pathol Int 2000 50 : 458.
21. Ordóñez NG. The diagnostic utility of immunohistochemistry in distinguishing between mesothelioma and renal cell carcinoma: a comparative study. Hum Pathol 2004 35 : 697.
22. Oji Y, Miyoshi Y, Koga S, et al. Overexpression of the Wilms' tumor gene WT1 in primary thyroid cancer. Cancer Sci 2003 94 : 606.
23. Bruening W, Gros P, Sato T, et al. Analysis of the 11p13 Wilms' tumor suppressor gene (WT1) in ovarian tumors. Cancer Invest 1993 11 : 393.
24. Nonomura N, Imazu T, Harada Y, et al. Molecular staging of testicular cancer using polymerase chain reaction of the testicular cancer-specific genes. Hinyokika Kiyo 1999 45 : 593.
25. Silberstein GB, Van Horn K, Strickland P, Roberts CT Jr., Daniel CW. Altered expression of the WT1 Wilms' tumor suppressor gene in human breast cancer. Proc Natl Acad Sci U S A 1997 94 : 8132.
26. Sheffield MV, Yee H, Dorvault CC, et al. Comparison of five antibodies as markers in the diagnosis of melanoma in cytologic preparations. Am J Clin Pathol 2002 118 : 930.
27. Ohsie SJ, Sarantopoulos GP, Cochran AJ, Binder SW. Immunohistochemical characteristics of melanoma. J Cutan Pathol 2008 35 : 433.